Dynamic control of local immunity parameters in patients with rhinosinusitis
Despite the large number of studies devoted to the problem of diagnosis and treatment of rhinosinusitis remains a discursive issue of effective diagnosis, optimal volume of medical support in such patients. Objective — to determine the degree of violation of the indices of local immunity of the mucous membranes of the upper respiratory tract in patients with rhinosinusitis. 60 patients were examined. All patients were divided into two groups: the first included 30 patients (control group), with rhinosinusitis on baseline therapy, and the second group consisted of 30 patients diagnosed with rhinosinusitis, to which the immunomodulator (inоsine pranobex) was added to the baseline therapy. The drug was administered at a dose of 500 mg. three times a day, within 7 days. In determining the level of sIgA we tested in nasal secretion in patients with rhinosinusitis, it was found that the levels of this secretory immunoglobulin were determined within the lower limits (from 0,72 to 0,98 mg/l) than the standard norms for persons in this age category (1,3–13,3 mg/l) and had no statistically significant difference. In a repeated study of the level sIgA in the subjects treated with baseline therapy and patients who received the immunomodulator (inоsine pranobex) in the basal therapy of rhinosinusitis, the following results were obtained: in the group of patients treated with baseline therapy, an increase in sIgA concentration was observed in 2,1 times, and in the group of patients with the addition of an immunomodulator — 2,6 times, which means a significant improvement in indices of local immunity when adding an immunomodulator to basic therapy. So, in patients with various forms of rhinosinusitis are a low baseline sIgA, indicating insufficient protection of the mucous membrane of the nasopharynx from infectious agents.
2. Zolotova, A. V. & Svistushkin, V. M. (2015). Sovremennye osobennosti techeniya ostrogo rinosinusita u detej. [Modern features of the course of acute rhinosinusitis in children]. Consilium Medicum, 1, 90–93.
3. Kryukov, A. I., Studenyj, M. E. & Artemev, M. E. (2012). Lechenie pacientov s rinosinusitami: vozmozhnosti konservativnogo i operativnogo vozdejstviya. [Treatment of patients with rhinosinusitis: the possibility of conservative and operative effects]. Medicinskij sovet – Medical advice, 11, 92–96.
4. Shadyev, T. H. (2013). Ostryj sinusit. [Acute sinusitis]. Russkij medicinskij zhurnal – Russian Medical Journal, 21, 11, 567–572.
5. Yarilin, A. A. (2010). Immunologiya. [Immunology]. Moskva: GEOTRA-MEDIA – Moscow: GEOTRA-MEDIA.
6. Fokkens, W. J., Lund, V. J. & Mullol, J. (2012). European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinol. Suppl, 23, 1–298.
7. Hamilos, D. L. (2011). Chronic rhinosinusitis: Epidemiology and medical management. J. Allergy Clin. Immunol., 128, 693–707.
8. Rosenfeld, R. M., Andes, D. & Bhattacharyya, N. (2007). Clinical practice guideline: adult sinusitis. Department of Otolaryngology, SUNY Downstate Medical Center and Long Island College Hospital, Brooklyn, 137 (3 Suppl), 1–31.
This work is licensed under a Creative Commons Attribution 4.0 International License.